{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-23-000044","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.625379+00:00","generated_at":"2026-06-08T02:06:03.619148+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xencor converts Genentech collaboration to royalty/milestone deal; up to $600M in milestones","bullets":["New agreement replaces cost/profit-sharing with tiered royalties (low double-digit to mid-teens percent) starting June 1, 2024.","Xencor eligible for up to $600M in milestones: $115M development, $185M regulatory, $300M sales-based.","Genentech assumes sole responsibility for all clinical, regulatory, and commercial activities post-effective date.","Original collaboration agreement remains in effect until May 31, 2024; Xencor had exercised royalty conversion option."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-23-000044","json":"https://secwatch.observer/filing/0001326732-23-000044.json","markdown":"https://secwatch.observer/filing/0001326732-23-000044.md","text":"https://secwatch.observer/filing/0001326732-23-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/0001326732-23-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/xncr-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:06:03.619148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"549a0a458b93de76f8d2fe4f1a234889a52e54df","claim":"Xencor Inc entered into Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $600 million in milestones; tiered royalties from low double-digit to mid-teens percentages (effective 2024-06-01).","evidence_excerpt":"On November 14, 2023, the Company entered into an Amended and Restated Collaboration and License Agreement (the “New Collaboration Agreement”) with Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and F. Hoffmann-La Roche Ltd, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/0001326732-23-000044-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Genentech, Inc. and F. Hoffmann-La Roche Ltd"},{"label":"Value","value":"$600 million in milestones; tiered royalties from low double-digit to mid-teens percentages"},{"label":"Effective","value":"2024-06-01"}],"fact_type":"material_agreement"},{"claim_id":"8b14e3aa992e972a406ec50ddbd1a2752c03f67d","claim":"Xencor Inc entered into Royalty Conversion arrangement under the New Collaboration Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at tiered royalties on a product-by-product and country-by-country basis ranging from low double-digit (effective 2024-06-01).","evidence_excerpt":"Pursuant to the Royalty Conversion, in connection with any program under the Original Collaboration Agreement, including XmAb306 (RO7310729), the Company will be entitled to receive tiered royalties on a product-by-product and country-by-country basis ranging from low double-digit to mid-teens percentages.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/0001326732-23-000044-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Genentech, Inc. and F. Hoffmann-La Roche Ltd"},{"label":"Value","value":"tiered royalties on a product-by-product and country-by-country basis ranging from low double-digit"},{"label":"Effective","value":"2024-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}